Abstract:e16509 Background: At present, bladder cancer is diagnosed mainly through cystoscopy as the "gold standard" method, which is invasive, costly, and painful for patients. Meanwhile, the current non-invasive liquid biopsy approaches, such as FISH or cytology, still do not show adequate performance in the diagnosis of bladder cancer because of the unsatisfactory sensitivity. Therefore, developing a novel method that performs higher sensitivity and specificity, especially negative predictive value(NPV) is an urgent issue to be addressed and will be very helpful for the clinical application. Methods: From October 2019 to October 2020, we designed a multicenter, prospective study, in which 321 hematuria patients were enrolled, including 218 males and 103 females, and their average age was 56. Based on the final pathological diagnosis, 121 patients were confirmed as bladder cancer and 200 samples were benign urinary diseases. 100ml urine samples were collected from each patient before the endoscopy examination. The Genetron Uro-18 assay, which included a 17 gene mutation panel and the methylation test on ONECUT2, was used in this study. The regions in the panel were selected based on the TCGA database, as well as previous publications. 321 urine DNA libraries were generated using multiplex PCR methods and then sequenced on the Ion S5 System. The CpG-sites on the ONECUT2 gene were detected by bisulfite-specific real-time PCR. Results: In these samples, a total of 205 oncogenic mutations were found in 13 genes in the panel. Mutations on TERT, PIK3CA, FGFR3, and TP53 genes showed significantly higher occurrence. 103 samples were found to be mutation-positive, 92 of which were pathologically confirmed as bladder cancers. When only gene mutations were considered, the sensitivity and specificity of this assay were 76.0% and 94.5%, respectively. The methylation of ONECUT2 had a performance in the test with a sensitivity of 74.4% and specificity of 93.0%. Combining the mutation panel with the ONECUT2 methylation test will improve the sensitivity (86.0%) of this assay, but slightly hampered the specificity (91.0%). The positive predictive value(PPV) and negative predictive value(NPV) of the combination were 85.2% and 91.5%. The sensitivity was as high as 91.5% when low-grade bladder cancer samples were excluded. In contrast, the sensitivity of cytology and FISH tests were only 48.4% and 62.0%. Conclusions: The novel urine-based liquid biopsy assay has excellent performances in the diagnosis of bladder cancer, with sensitivity and NPV reaching 86.0% and 91.5%, which improved significantly than cytology and FISH tests. Thus this assay will be more beneficial for patients with urinary diseases which significantly reduces the current burden of repeat cystoscopies and cytology tests.

Clinical diagnostic study of UCA1 gene for bladder urothelial carcinoma

[Evaluation of novel gene UCA1 as a tumor biomarker for the detection of bladder cancer].

Lncrna-Uca1 in the Diagnosis of Bladder Cancer

Correlation analysis of the expression intensity of novel gene UCA1 and tumor grade of urothelial carcinoma

Diagnostic accuracy of DnA cytometry and urinary cytology in urothelial carcinomas

Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial

Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma

The Clinical Application of Fluorescence in Situ Hybridization in Diagnosing Urothelial Carcinoma

Utility of fluorescence in situ hybridization analysis for detecting upper urinary tract-urothelial carcinoma

A Urine-Based Liquid Biopsy Method for Detection of Upper Tract Urinary Carcinoma

Urinary BLCA1 is Specific for Urothelial Cancer Detection in Chinese Ethnicity.

The value of combined detection of BLCA-1 and BLCA-4 in urine for early diagnosis and surveillance for bladder cancer

Detection of Urothelial Carcinoma, Upper Tract Urothelial Carcinoma, Bladder Carcinoma, and Urothelial Carcinoma with Gross Hematuria Using Selected Urine-Dna Methylation Biomarkers: A Prospective, Single-Center Study

The expression and clinical significance of UCA1 in renal cell carcinoma

Urothelial Carcinoma Detection Based on Copy Number Profiles of Urinary Cell-Free DNA by Shallow Whole-Genome Sequencing.

Clinical utility of fluorescence in situ hybridization assay for urothelial carcinoma and analysis of reasons of missed diagnosis

A multicenter, prospective evaluation of a urine-based assay for bladder cancer diagnosis.

Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma

Clinical utility of fluorescence in situ hybridization improves the sensitivity in the diagnosis of upper urinary tract urothelial carcinoma]

UriFind assay and association with whole course management of urothelial carcinoma in a large multicentric, prospective China cohort.

Application of Double Fluorescence in Situ Hybridization Technology in the Diagnosis of Bladder Urothelial Carcinoma